Initial patients dosed in multiple cohorts of Ph 1 dose-expansion study of KTX-1001, mezigdomide, and SoC combo in t(4;14) multiple myeloma
“We are excited to see the dose expansion cohorts open in the U.S. and EU and to see continued momentum for KTX-1001, an oral therapy we believe holds great promise to transform outcomes in multiple myeloma,” said Terry Connolly, Ph.D., President and Chief Executive Officer of K36. “Despite advances that have extended survival for people living with MM, this challenging blood cancer remains incurable, and most patients eventually relapse. There is an urgent need for therapies that are both effective and convenient, enabling patients to receive care in community settings while also maintaining quality of life. We are deeply grateful to the patients, investigators, and their care teams for their commitment to advancing this important research. The favorable tolerability profile of KTX-1001, together with promising early signs of clinical activity, underscores its potential as a first-in-class targeted therapy for patients with t(4;14) multiple myeloma, and our agreement with BMS enables us to further explore its potential benefit in novel combinations.”
Share:
More News
“The positive outcome of our pre-IND interactions with the FDA reinforces the development pathway for MaaT034 and supports its continued advancement toward the clinic. It also represents an important step in MaaT Pharma’s expansion into immuno-oncology, highlighting the broader potential of our first in class co-cultivated microbiome donor-independent platform across
“Patients with metastatic RAS G12D non-squamous NSCLC, occurring in approximately 4% of cases, represent an underserved population, with no approved targeted treatment options. Initial clinical data evaluating zoldonrasib in combination with standard of care pembrolizumab and platinum doublet chemotherapy in patients with previously untreated metastatic RAS G12D non-squamous NSCLC showed
“At Georgiamune, we are focused on uncovering novel mechanisms that control immune-cell function and translating that biology into first-in-class medicines across autoimmune disease and oncology,” said Samir N. Khleif, M.D., Founder and Chief Executive Officer of Georgiamune. “GIM-621 is one of multiple programs to emerge from that work, alongside three
“Our team’s outstanding execution has enabled us to rapidly advance three programs into the clinic in 2026 and make significant progress in developing next-generation IO, ADC and combination therapies. Together with our partner, Kelun-Biotech, we have achieved seven IND clearances to date, and by mid-2027, we expect more than 2,000